UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreatic adenocarcinoma

European journal of cancer (1990), 2024-04, Vol.201, p.113950-113950, Article 113950

2024

Volltextzugriff (PDF)

A phase 2 study of zanubrutinib in previously treated B‐cell malignancies intolerant to ibrutinib and/or acalabrutinib: Preliminary results for patients with CLL/SLL

Hematological oncology, 2023-06, Vol.41 (S2), p.469-471

2023

Volltextzugriff (PDF)

Introductory Address at the Inaugural Gathering of “Laudato Si’ and the U.S. Catholic Church”

Journal of moral theology, 2020-04, Vol.9 (SI1)

Daniel J. Misleh

2020

Volltextzugriff (PDF)

PRELIMINARY RESULTS OF THE PHASE 2 STUDY OF ZANUBRUTINIB IN PATIENTS WITH PREVIOUSLY TREATED B‐CELL MALIGNANCIES INTOLERANT TO IBRUTINIB AND/OR ACALABRUTINIB

Hematological oncology, 2021-06, Vol.39 (S2)

2021

Volltextzugriff (PDF)

1625P Multicenter, randomized, parallel group, phase II study to establish the efficacy and safety of CBP501, cisplatin, and nivolumab for ≥ third-line treatment of patients with exocrine pancreatic cancer and WBC <10,000/mm3

Annals of oncology, 2023-10, Vol.34, p.S900-S900

2023

Volltextzugriff (PDF)

17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023

Hematological oncology, 2023-06, Vol.41 Suppl 2, p.469

2023

Volltextzugriff (PDF)

Laudato Si' and Catholic Health Care

Health progress (Saint Louis, Mo.), 2016-05, Vol.97 (3), p.46-49

2016

Volltextzugriff (PDF)

195TiP A first-in-human, phase I a/b dose escalation and expansion study to evaluate RBS2418 as monotherapy and in combination with pembrolizumab in subjects with advanced unresectable, recurrent or metastatic tumors

Immuno-oncology technology, 2022-12, Vol.16, p.100307, Article 100307

2022

Volltextzugriff (PDF)

Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma

Haematologica (Roma), 2014-11, Vol.99 (11), p.1738-1745

2014

Volltextzugriff (PDF)

Post-transplant lymphoproliferative disorder in adult lung transplant recipients: A report on twenty-seven patients

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.19521-19521

2008

Volltextzugriff (PDF)

Emerging Issues: The Faith Communities and the Criminal Justice System

Journal of religion & spirituality in social work, 2004-03, Vol.23 (1-2), p.111-131

2004

Volltextzugriff (PDF)

Presentation, treatment and outcome of 24 patients with Posttransplant Lymphoproliferative Disorder (PTLD) after lung transplantation

The Journal of heart and lung transplantation, 2005-02, Vol.24 (2), p.S103-S103

2005

Volltextzugriff (PDF)

Faithful Citizenship and Climate Change: Reclaiming Christian Principles of Prudence, Poverty and the Common Good

Journal of religion & society, 2008-01, Vol.10, p.150-163

Misleh, Daniel J

2008

Volltextzugriff (PDF)

Laudato Si' and Catholic Health Care

Health Progress, 2016-05, Vol.97 (3), p.47

2016

Volltextzugriff (PDF)

Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan

Clinical cancer research, 2017-10, Vol.23 (19), p.5711-5719

2017

Volltextzugriff (PDF)

Post-transplant lymphoproliferative disorder after lung transplantation: A review of 35 cases

The Journal of heart and lung transplantation, 2012-03, Vol.31 (3), p.296-304

2012

Volltextzugriff (PDF)

868P Phase II trial of ozuriftamab vedotin (BA3021), a conditionally active biologic (CAB)-ROR2-ADC, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)

Annals of oncology, 2024-09, Vol.35, p.S622-S623

2024

Volltextzugriff (PDF)

665P Safety, PK, immune activation, and clinical outcomes with RBS2418 treatment, an oral ENPP1 inhibitor, alone or in combination with pembrolizumab in advanced solid tumors

Annals of oncology, 2024-09, Vol.35, p.S523-S523

2024

Volltextzugriff (PDF)

575P Phase Ib/II study of ompenaclid (RGX-202-01), a first-in-class oral inhibitor of the creatine transporter SLC6A8, in combination with FOLFIRI and bevacizumab (BEV) in RAS mutated (RASmt) second-line (2L) advanced/metastatic colorectal cancer (mCRC): Updated results

Annals of oncology, 2024-09, Vol.35, p.S467-S467

2024

Volltextzugriff (PDF)

Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance)

Journal of clinical oncology, 2021-08, Vol.39 (22), p.2486-2496

2021

Volltextzugriff (PDF)

1025MO Preliminary safety, pharmacokinetics and immunomodulatory activity of RBS2418, an oral ENPP1 inhibitor, alone and in combination with pembrolizumab in patients with solid tumors

Annals of oncology, 2023-10, Vol.34, p.S623-S624

2023

Volltextzugriff (PDF)

646P Phase Ib/II study of ompenaclid (RGX-202-01), afirst-in-class oral inhibitor of the creatine transporter SLC6A8, in combination with FOLFIRI and bevacizumab (BEV) in RAS mutated (RASm) second-line (2L) advanced/metastatic colorectal cancer (mCRC)

Annals of oncology, 2023-10, Vol.34, p.S454-S455

2023

Volltextzugriff (PDF)

Genomic Landscape of Ibrutinib- and/or Acalabrutinib-intolerant Patients with B-cell Malignancies Treated with Zanubrutinib in a Phase 2 Study

Blood, 2023-11, Vol.142 (Supplement 1), p.6510-6510

2023

Volltextzugriff (PDF)

A two-part, phase II, multi-center study of the ERK inhibitor ulixertinib (BVD-523) for patients with advanced malignancies harboring MEK or atypical BRAF alterations (BVD-523-ABC)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS3172-TPS3172

2022

Volltextzugriff (PDF)

Whole transcriptome analysis of tumors with discordant oncotype and MammaPrint results in the FLEX trial

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.556-556

2022

Volltextzugriff (PDF)

1 – 25 von 34

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(31)
Mit Volltextzugriff
(30)

Publikationsform

Artikel
(33)
magazinearticle
(1)

Sprache

Englisch
(34)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(8)
Science & Technology
(8)
Humans
(7)
Oncology
(6)
Aged
(4)
Chemotherapy
(4)
Female
(4)
Male
(4)
Middle Aged
(3)
Adult
(2)
Aged, 80 And Over
(2)
Antibodies, Monoclonal, Humanized - Administration & Dosage
(2)
Biomarkers
(2)
Climate Change
(2)
Clinical Trials
(2)
Diarrhea
(2)
Immunotherapy
(2)
Kaplan-Meier Estimate
(2)
Lung Cancer
(2)
Metastases
(2)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreatic adenocarcinoma

A phase 2 study of zanubrutinib in previously treated B‐cell malignancies intolerant to ibrutinib and/or acalabrutinib: Preliminary results for patients with CLL/SLL

Introductory Address at the Inaugural Gathering of “Laudato Si’ and the U.S. Catholic Church”

PRELIMINARY RESULTS OF THE PHASE 2 STUDY OF ZANUBRUTINIB IN PATIENTS WITH PREVIOUSLY TREATED B‐CELL MALIGNANCIES INTOLERANT TO IBRUTINIB AND/OR ACALABRUTINIB

1625P Multicenter, randomized, parallel group, phase II study to establish the efficacy and safety of CBP501, cisplatin, and nivolumab for ≥ third-line treatment of patients with exocrine pancreatic cancer and WBC <10,000/mm3

17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023

Laudato Si' and Catholic Health Care

195TiP A first-in-human, phase I a/b dose escalation and expansion study to evaluate RBS2418 as monotherapy and in combination with pembrolizumab in subjects with advanced unresectable, recurrent or metastatic tumors

Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma

Post-transplant lymphoproliferative disorder in adult lung transplant recipients: A report on twenty-seven patients

Emerging Issues: The Faith Communities and the Criminal Justice System

Presentation, treatment and outcome of 24 patients with Posttransplant Lymphoproliferative Disorder (PTLD) after lung transplantation

Faithful Citizenship and Climate Change: Reclaiming Christian Principles of Prudence, Poverty and the Common Good

Laudato Si' and Catholic Health Care

Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan

Post-transplant lymphoproliferative disorder after lung transplantation: A review of 35 cases

868P Phase II trial of ozuriftamab vedotin (BA3021), a conditionally active biologic (CAB)-ROR2-ADC, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)

665P Safety, PK, immune activation, and clinical outcomes with RBS2418 treatment, an oral ENPP1 inhibitor, alone or in combination with pembrolizumab in advanced solid tumors

575P Phase Ib/II study of ompenaclid (RGX-202-01), a first-in-class oral inhibitor of the creatine transporter SLC6A8, in combination with FOLFIRI and bevacizumab (BEV) in RAS mutated (RASmt) second-line (2L) advanced/metastatic colorectal cancer (mCRC): Updated results

Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance)

1025MO Preliminary safety, pharmacokinetics and immunomodulatory activity of RBS2418, an oral ENPP1 inhibitor, alone and in combination with pembrolizumab in patients with solid tumors

646P Phase Ib/II study of ompenaclid (RGX-202-01), afirst-in-class oral inhibitor of the creatine transporter SLC6A8, in combination with FOLFIRI and bevacizumab (BEV) in RAS mutated (RASm) second-line (2L) advanced/metastatic colorectal cancer (mCRC)

Genomic Landscape of Ibrutinib- and/or Acalabrutinib-intolerant Patients with B-cell Malignancies Treated with Zanubrutinib in a Phase 2 Study

A two-part, phase II, multi-center study of the ERK inhibitor ulixertinib (BVD-523) for patients with advanced malignancies harboring MEK or atypical BRAF alterations (BVD-523-ABC)

Whole transcriptome analysis of tumors with discordant oncotype and MammaPrint results in the FLEX trial

Suchergebnisse filtern